top of page
May 3, 2023
Focus on the mechanism of action of anti-tumor activity for lead asset YB-200
Dr. Katrin Rupalla shared data on the mechanism of action and preclinical anti-tumor activity of YB-200 at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT) 2023. YB-200 is our lead CEACAM1/5 immune agonistic antibody.
We were honored to present Abstract Number 197. Poster title was "YB-200, a novel antibody targeting CEACAM1/5, induces complete response in syngeneic liver Hepa1-6 tumor-bearing mice and modulates the immune response." You can learn more in our press release.
bottom of page